20:54 , Aug 8, 2018 |  BC Extra  |  Politics & Policy

First generic approved under FDA pathway to foster competition

FDA approved the first generic drug under a new pathway aimed at curbing prices of generic drugs that have no competitor. The inaugural approval went to Apotex Inc. (Toronto, Ontario) for its potassium chloride oral...
17:30 , Jul 20, 2018 |  BC Week In Review  |  Company News

PTAB upholds Gilenya patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board upheld claims 1-6 of U.S. Patent No. 9,187,405 covering multiple sclerosis drug Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN). PTAB instituted...
18:45 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; cancer

INDICATION: Colitis; colorectal cancer Mouse studies suggest iron chelation or superoxide reduction could help treat colitis or colitis-induced colorectal cancer. In a mouse model of acute colitis, the iron-chelating agent Ferriprox deferiprone increased body weight...
03:19 , Nov 17, 2017 |  BC Week In Review  |  Company News

CAFC affirms Apotex biosimilars do not infringe Amgen patent

The U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court ruling that two biosimilars from Apotex Inc. (Toronto, Ontario) do not infringe a patent held by Amgen Inc. (NASDAQ:AMGN). Amgen sought...
23:16 , Nov 13, 2017 |  BC Extra  |  Company News

CAFC affirms Apotex biosimilars do not infringe Amgen patent

The U.S. Court of Appeals for the Federal Circuit affirmed a district court ruling that two biosimilars from Apotex Inc. (Toronto, Ontario) do not infringe a patent held by Amgen Inc. (NASDAQ:AMGN). Amgen sought a...
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
21:08 , Sep 15, 2017 |  BC Week In Review  |  Company News

Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Sept. 8 that it had transferred ownership of six patents...
00:45 , Sep 9, 2017 |  BC Extra  |  Company News

Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Friday that it had transferred ownership of six patents covering...
21:45 , Jun 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In Science last month, a University of Illinois -led group...
00:00 , Apr 22, 2017 |  BioCentury  |  Finance

Buying local

CanSino Biologics Inc. ’s investors are hoping a $65 million venture round will be enough to help the company launch a trio of products by 2019 to tap China’s growing demand for vaccines. Future Industry...